David Rescott
Stock Analyst at Truist Securities
(4.05)
# 560
Out of 5,133 analysts
77
Total ratings
68.85%
Success rate
8.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Rescott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Buy | $21 → $23 | $17.88 | +28.64% | 8 | Dec 18, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $88 → $87 | $83.84 | +3.77% | 7 | Dec 16, 2025 | |
| HAE Haemonetics | Maintains: Outperform | $87 → $99 | $78.82 | +25.60% | 2 | Dec 15, 2025 | |
| MDT Medtronic | Maintains: Neutral | $103 → $109 | $96.42 | +13.05% | 8 | Nov 19, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $63 → $70 | $61.33 | +14.14% | 6 | Nov 13, 2025 | |
| BSX Boston Scientific | Maintains: Outperform | $123 → $128 | $94.14 | +35.97% | 9 | Oct 1, 2025 | |
| PEN Penumbra | Maintains: Buy | $300 → $310 | $300.97 | +3.00% | 31 | Jul 30, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $111 → $110 | $81.08 | +35.67% | 3 | Apr 25, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $600 → $575 | $561.82 | +2.35% | 3 | Apr 23, 2025 |
SI-BONE
Dec 18, 2025
Maintains: Buy
Price Target: $21 → $23
Current: $17.88
Upside: +28.64%
Edwards Lifesciences
Dec 16, 2025
Maintains: Neutral
Price Target: $88 → $87
Current: $83.84
Upside: +3.77%
Haemonetics
Dec 15, 2025
Maintains: Outperform
Price Target: $87 → $99
Current: $78.82
Upside: +25.60%
Medtronic
Nov 19, 2025
Maintains: Neutral
Price Target: $103 → $109
Current: $96.42
Upside: +13.05%
LivaNova
Nov 13, 2025
Maintains: Outperform
Price Target: $63 → $70
Current: $61.33
Upside: +14.14%
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $123 → $128
Current: $94.14
Upside: +35.97%
Penumbra
Jul 30, 2025
Maintains: Buy
Price Target: $300 → $310
Current: $300.97
Upside: +3.00%
Merit Medical Systems
Apr 25, 2025
Maintains: Outperform
Price Target: $111 → $110
Current: $81.08
Upside: +35.67%
Intuitive Surgical
Apr 23, 2025
Maintains: Outperform
Price Target: $600 → $575
Current: $561.82
Upside: +2.35%